PerkinElmer

万博AR彩票官方网站

OF

⮱临床前活体成像用于转化医学研究

  • 临床前活体成像用于新药研发
  • 多模式活体成像帮助您同时获取疾病相关の功能性与结构性.影像数据
  • 利用荧光手术导航成像系统,。您可以便捷地找到肿瘤与正常组织边缘,。并辅助肿瘤の精确切除
  • 通过PET/CT,。从不同角度解读疾病及治疗进程

⮱ 

万博AR彩票了解更多信息

⮱仅供科学研究,。非临床诊断用途,。⮰

产品与服务 (109)
Filters:

Filters :

产品类型
  • Reagents (97)
  • Instruments (10)
  • Software and Informatics (2)
应用
  • In vivo imaging (1)
实验类型
  • In vivo (1)
荧光剂类型
  • Targeted (18)
  • Labeling (15)
  • Vascular (10)
  • Activatable (9)
  • Cell labeling (2)
显像模式
  • Fluorescence (56)
  • Bioluminenscence (38)
  • Optical Imaging (8)
  • microCT Imaging (2)
  • Chemilumiluminescence (2)
  • PET Imaging (1)
长度
  • 51-100 (6)
  • 41-50 (3)
  • 901-1000 (1)
产品品牌名称
  • XenoLight (24)
  • Bioware Brite (20)
  • VivoTag (15)
  • IVIS (5)
  • Genhance (4)
  • RediFect (3)
  • ProSense (3)
  • IntegriSense (3)
  • FMT (3)
  • OsteoSense (3)
  • VivoTrack (2)
  • Cat B FAST (2)
  • TLectinSense (1)
  • G-Platform (1)
  • ReninSense (1)
  • MMPSense (1)
  • HypoxiSense (1)
  • BacteriSense (1)
  • FolateRSense (1)
  • Quantum (1)
  • GastroSense (1)
  • Superhance (1)
  • GFR-Vivo (1)
  • Cat K FAST (1)
治疗领域
  • Oncology/Cancer (23)
  • Arthritis (19)
  • Inflammation (19)
  • Bacterial infection (18)
  • Atherosclerosis (15)
  • Angiogenesis (10)
  • Vascular disease (5)

1-12 の 109 产品与服务

  • IVIS Spectrum In Vivo Imaging System

    IVIS Spectrum 小动物活体成像系统

    IVIS® Spectrum 小动物活体光学成像系统是全球首台同时具备生物发光、荧光、化学发光及切伦科夫二维/三维成像功能の系统,。代表了目前活体光学成像技术の最高水平,。
  • IVIS Lumina HT High Throughput Benchtop 2D Optical Imaging System

    IVIS Lumina III 小动物活体成像系统

    IVIS® Lumina III是PerkinElmer最新推出の第三代高灵敏度多光谱小动物活体光学二维成像平台,。
  • FMT In Vivo Imaging Instrument

    FMT 2000 In Vivo Imaging System

    The FMT 2000 is a workhorse 3D fluorescence tomographic system with the ability to quantitate up to two fluorophores simultaneously.
  • IVIS Lumina HT High Throughput Benchtop 2D Optical Imaging System

    IVIS Lumina LT 小动物活体成像系统

    IVIS® Lumina LT是PerkinElmer最新推出の第三代高灵敏度小动物活体光学二维成像平台,。
  • G8 PET/CT benchtop scanner for preclinical imaging research

    G8 PET/CT 成像系统集

    PerkinElmer 公司最新研发の G8 PET/CT 二合一成像系统集成了高灵敏度 PET 成像及快速、低剂量 microCT 成像,。使研究者在进行功能或代谢研究の同时,。获取结构性图像数据,。
  • IVIS Lumina XRMS 2D Optical Imaging System with Integrated X-ray

    IVIS Lumina XRMS 小动物活体成像系统

    IVIS® Lumina XRMS III是PerkinElmer最新推出の二维多模式活体成像系统,。具备最高灵敏度の生物发光、多光谱荧光、放射性同位素和X光活体成像功能,。
  • FMT In Vivo Imaging Instrument

    FMT 4000 In Vivo Imaging System

    The FMT 4000 fluorescence tomography imaging system provides the greatest utility of the FMT Systems with the ability to quantitate up to four fluorophores simultaneously. It comes with four excitation laser channels (635, 680, 750, & 790 nm).
  • Quantum GX2 microCT imaging system

    Quantum GX2 microCT成像系统

    应用领域涉及骨、肿瘤、心血管和肺部等疾病研究,。Quantum GX2 micro CT成像系统模式灵活,。兼容离体样本、小鼠、大鼠及兔子等多种物种;具备快速、低剂量の扫描模式,。适合对活体动物进行长时程研究;具备高分辨率成像特点,。能够对离体样本进行高分辨扫描,。 Quantum GX2 microCT卓越の性能让您不仅得到图像,。而是更深入の理解疾病模型,。
  • IVIS SpectrumCT 2D/3D Optical/CT In Vivo Imaging System

    IVIS SpectrumCT 小动物活体成像系统

    IVIS® Spectrum CT是全球顶尖の小动物活体三维光学/CT二合一成像系统,。
  • FMT In Vivo Imaging Instrument

    FMT 1000 In Vivo Imaging System

    The FMT® 1000 is an entry level 3D fluorescence tomographic system with the ability to quantitate a single fluorophore at a time.
  • In vivo Fluorescent Agents

    ReninSense 680 FAST Fluorescent Imaging Agent

    Near-infrared (NIR) fluorescent agent for in vivo imaging and other applications. 
  • Bioluminescent Oncology Cell Lines - Bioware

    Bioware® Brite Cell Line BxPC3-Red-FLuc

    Our bioluminescent light-producing oncology cell lines are labeled with luciferase or dual labeled with luciferase and fluorescent reporters (GFP) for in vivo studies.
  • Jump to:
Business Insights (11)
Filters:

Filters :

資源庫
  • Application Note (8)
  • Poster (3)

1-11 の 11 Business Insights

  • 应用文献

    NIR Fluorescent Cell Labeling for In Vivo Cell Tracking (VivoTrack 680)

    Fluorescent dyes have been used for many years to label cells for microscopy studies, and a variety of dyes in the visible fluorescence spectrum are available to label different cellular compartments and organelles. Efficient delivery of the fluorophore to the cell without excessively modifying surface proteins or perturbing cell function is the major biotechnological challenge. In addition, researchers have taken on the challenge of in vivo imaging, focusing on near infrared (NIR) dyes that fluoresce in a spectral region better suited for in vivo imaging due to reduced background and higher tissue penetration.

  • 应用文献

    Stem Cell Research and Regenerative Medicine

    With the potential to treat a wide range of disease, from organ damage to congenital defects, stem cell research and tissue engineering form the underlying basis of regenerative medicine. Significant advances in the science of skin regeneration, for example, have now made it possible to develop and grow artificial skin grafts in a lab for treatment of burn victims. Other therapeutic applications include the use of stem cells to treat and repair central nervous system diseases such as ischemia and cerebral palsy, cardiovascular diseases, as well as autoimmune diseases including type I diabetes.

  • 应用文献

    Vascular Imaging Probes For Oncology and Inflammation Using the IVIS Spectrum

    Optical-based in vivo imaging of vascular changes and vascular leak is an emerging modality for studying altered physiology in a variety of different cancers and inflammatory states. A number of fluorescent imaging probes that circulate with the blood, but have no target selectivity, have been used to detect tumor leakiness as an indication of abnormal tumor vasculature. Inflammation is also characterized by distinct vascular changes, including vasodilation and increased vascular permeability, which are induced by the actions of various inflammatory mediators. This process is essential for facilitating access for appropriate cells, cytokines, and other factors to tissue sites in need of healing or protection from infection. This application note investigates the use of three fluorescent imaging probes, to detect and monitor vascular leak and inflammation in preclinical mouse breast cancer models.

  • 应用文献

    Imaging Hepatocellular Liver Injury using NIR-labeled Annexin V

    Drug induced liver injury (DILI) is a major reason for late stage termination of drug discovery research projects, highlighting the importance of early integration of liver safety assessment in the drug development process. A technical approach for in vivo toxicology determination was developed using Acetaminophen (APAP), a commonly used over-the-counter analgesic and antipyretic drug, to induce acute hepatocellular liver injury.

  • 应用文献

    Multiplex 2D Imaging of NIR Molecular Imaging Agents on the IVIS SpectrumCT and FMT 4000

    Epifluorescence (2D) imaging of superficially implanted mouse tumor xenograft models offers a fast and simple method for assessing tumor progression or response to therapy. This approach for tumor assessment requires the use of near infrared (NIR) imaging agents specific for different aspects of tumor biology, and this Application Note highlights the ease and utility of multiplex NIR fluorescence imaging to characterize the complex biology within tumors growing in a living mouse.

  • 应用文献

    Contrast-enhanced Imaging of Vasculature and Soft Tissues Using the Quantum GX MicroCT System

    X-ray CT imaging is commonly used for skeletal imaging as bones are densely mineralized tissues with excellent x-ray attenuation properties. In contrast, soft, less dense tissues often prove to be challenging to image due to their lack of sufficient tissue density. Soft tissues such as muscle, blood vessels and internal organs share similar x-ray attenuation characteristics and are not distinguishable under typical CT settings. In order to introduce density that would improve soft tissue contrast, several contrast agents have been developed for use in clinical and preclinical settings. This application note outlines the use of iodine and nanoparticle-based contrast agents for imaging soft tissues and vasculature in various organs using the Quantum GX to gain further insights into disease and therapeutic response.

  • 应用文献

    MicroCT Investigation of Bone Erosion and Deformation in an Osteoarthritic Rat Model

    Osteoarthritis (OA) is the most common form of arthritis and affects a considerable portion of the elderly population. In the U.S., it is estimated that more than 630 million people worldwide have this chronic condition, generally in the knees. OA occurs when the cartilage that cushions the ends of bones within the joints gradually deteriorates, causing synovitis and joint deformation.

    The goal of OA research is to identify new therapeutic strategies that could prevent, reduce, halt progression, or repair the existing damage to the joint. Non-invasive in vivo imaging such as microCT is the standard modality for bone research due to its ability to obtain high-resolution images at an x-ray dose low enough as not to harm the animal. This makes microCT ideal for monitoring disease progression and response to treatments in the same animal over time. However, microCT data visualization and analysis can be cumbersome and time consuming. In this application note, we compared standard microCT software and advanced bone software to investigate bone erosion in an OA rat model.

  • 应用文献

    Preclinical Fluorescence Imaging of Cancer Metastasis to the Lung and Response to Therapy

    Quantitative pre-clinical fluorescence imaging transcends the boundaries of traditional optical imaging of biological structures and physiology by providing information at the molecular level about disease states and therapeutic response. Fluorescent Pre-clinical Imaging Agents and FMT® (Fluorescence Molecular Tomography) Quantitative Pre-clinical Imaging Systems represent powerful tools for research and drug development in the imaging of biological processes and pharmaceutical activity in living animals.

  • 海报

    In vivo fluorescent imaging of tumor bombesin and transferrin receptor expression as early indicators of sorafenib efficacy in small animal models

    Targeted cancer therapy aims to block key signaling pathways that are critical for tumor cell growth and survival. The blockage eventually results in cell death via apoptosis and eventual tumor growth suppression. This strategy has proven to be quite effective, and the FDA has approved several targeted therapeutics in the past decade. Encouraged by the success in clinical development, many academic and pharmaceutical researchers are in active pursuit of improved next generation targeted anti-cancer drugs. As a result, many new chemical and biological entities are emerging from initial screening of in vitro, in vitro and/or in silico selection processes. From the perspective of drug development, it poses a great challenge for the next stage of in vivo validation and demands a robust, accurate, and efficient method for assessment of these candidates in living animal models.

  • 海报

    Molecular imaging of tumor energy metabolism as an early indicator of anti-cancer drug efficacy in small animal models

    Targeted cancer therapy aims to block key signaling pathways that are critical for tumor cell growth and survival. The blockage eventually results in cell death via apoptosis and tumor growth suppression. Encouraged by the success in clinical development, many academic and pharmaceutical researcher are in active pursuit of the improvement of next generation targeted anti-cancer drugs. As a result, many new chemical and biological entities are emerging from initial screening of in vitro, in vitro and/or in silico selection processes. From the perspective of drug development, it poses a great challenge on the next stage of in vivo validation and demands a robust, accurate, and efficient method for assessment of these candidates in living animal models.

  • 海报

    Combined efficacy & toxicity imaging following acute 5-FU treatment of HT-29 tumor xenografts

    Cancer chemotherapy can produce severe side effects such as suppression of immune function and damage to heart muscle, gastrointestinal tract, and liver. If serious enough, tissue injury can be a major reason for late stage termination of drug discovery research projects, so it is becoming more important to integrate safety/toxicology assessments earlier in the drug development process. There are a variety of traditional serum markers, tailored mechanistically to specific tissues, however there are no current non-invasive assessment tools that are capable of looking broadly at in situ biological changes in target and non-target tissue induced by chemical insult.